Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | IAPP | P10997 | 3/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7332325 | 0.90 | FFAR1 (0.58) | HPGDFFAR1SLC5A1SLC5A2LMNA | |
| SCHEMBL11539459 | 0.86 | IAPP (0.58) | HPGDIAPPFFAR1SLC5A1SLC5A2 | |
| SCHEMBL1051720 | 0.82 | IAPP (0.61) | IAPPFFAR1SLC5A1SLC5A2TDP1 | |
| SCHEMBL1053043 | 0.82 | IAPP (0.66) | HPGDIAPPSLC5A1SLC5A2MEN1 | |
| SCHEMBL8833730 | 0.82 | TDP1 (0.56) | HPGDIAPPKMT2ATDP1LMNA | |
| Butyric Acid SCHEMBL30807147 | 0.81 | FFAR1 (0.65) | HPGDFFAR1ALDH1A1LMNA | |
| SCHEMBL28238496 | 0.81 | IAPP (0.58) | IAPPTDP1ALDH1A1LMNAGAA | |
| SCHEMBL10756041 | 0.81 | FFAR1 (0.50) | HPGDFFAR1SLC5A1SLC5A2LMNA | |
| SCHEMBL10853169 | 0.81 | FFAR1 (0.64) | FFAR1SLC5A1SLC5A2 | |
| SCHEMBL9709577 | 0.81 | IAPP (0.59) | IAPPFFAR1POLBF2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| CN-1749252-B | Compounds useful to treat retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2011-06-08 | — | — | CN | disclosed |
| CN-1329378-C | Compounds for the treatment of retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2007-08-01 | — | — | CN | disclosed |
| CN-1749252-A | Compounds useful to treat retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-22 | — | — | CN | disclosed |
| CN-1539825-A | Compounds for the treatment of retroviral infections | �������Ŷ���Լ��������˾ | 2004-10-27 | — | — | CN | disclosed |
| CN-1154642-C | Compounds for the treatment of retroviral infections | �������Ŷ���Լ��������˾ | 2004-06-23 | — | — | CN | disclosed |
| EP-0758327-B1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6169181-B1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2001-01-02 | — | — | US | disclosed |
| US-5852195-A | Pyranone compounds useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| CN-1150424-A | Compounds for the treatment of retroviral infections | UPJOHN CO (US) | 1997-05-21 | — | — | CN | disclosed |
| EP-0758327-A1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | HPGD 2382/4885IAPP 195/4885FFAR1 1287/4885 |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | HPGD 2382/4885IAPP 195/4885FFAR1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.